1997
DOI: 10.1002/(sici)1097-0142(19970601)79:11<2107::aid-cncr7>3.3.co;2-l
|View full text |Cite
|
Sign up to set email alerts
|

High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B‐cell chronic lymphocytic leukemia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
15
0
2

Year Published

1998
1998
2014
2014

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 13 publications
(17 citation statements)
references
References 0 publications
0
15
0
2
Order By: Relevance
“…Nowadays, based on a type 1 level of evidence and due to the existence of several more efficacious options, chlorambucil is only indicated when palliation of symptoms is the goal of treatment, given daily until a maximal response is reached or All others toxicity appears. Several clinical trials [77][78][79] have reached the following conclusions:…”
Section: Single-agent Treatmentmentioning
confidence: 92%
See 1 more Smart Citation
“…Nowadays, based on a type 1 level of evidence and due to the existence of several more efficacious options, chlorambucil is only indicated when palliation of symptoms is the goal of treatment, given daily until a maximal response is reached or All others toxicity appears. Several clinical trials [77][78][79] have reached the following conclusions:…”
Section: Single-agent Treatmentmentioning
confidence: 92%
“…The rationale for their use stemmed from their effective activity in low-grade lymphomas. Among others, the most used have been CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) [79], CAP (cyclophosphamide, doxorubicin and prednisone) [80] and COP (cyclophosphamide, vincristine and prednisone) [81]. All regimes obtained higher response rates but none showed a benefit in terms of survival a some higher toxicity.…”
Section: Combination Chemotherapymentioning
confidence: 99%
“…TTM is a simple clinical parameter that takes into account tumour burden in major tumour cell compartments (Fig A). It has been validated in prognostic studies and in several multicentre international clinical trials both for disease progression rate and responsiveness to therapy, and proved to be useful because of its continuous quantitative character based on tumour parameters and not on bone marrow failure parameters (Jaksic et al , ; CLL Trialists Collaborative Group, ; EORTC Leukemia Cooperative Group, ).…”
Section: Kinetic Model Of Tumour Load Changes After Therapymentioning
confidence: 99%
“…Inclusion of an anthracycline in the combination did not affect outcome. In one of these trials involving 228 patients, 48 both the OR rate (90 versus 75%) and median overall survival (68 versus 47 months) were greater with high-dose chlorambucil (15 mg/day until toxicity) than with the low-dose French CHOP regimen.…”
Section: Cyclophosphamide Combination Regimensmentioning
confidence: 99%